Topical Steroid Withdrawal and the Push for Clinical Validation

Clinically Reviewed by Dr. C. Alahakoon | Published on 24 July 2026

Topical Steroid Withdrawal and the Push for Clinical Validation - Glowgau Clinical Analysis

Topical Steroid Withdrawal and the Push for Clinical Validation

Topical steroid withdrawal (TSW) has gained clinical recognition in recent years, with growing discussion about a dedicated ICD-10 code. But the regulatory landscape is more nuanced than some headlines suggest.

Short answer

Topical steroid withdrawal is a recognized clinical phenomenon where skin deteriorates after discontinuing prolonged topical corticosteroid use. While dermatology literature and advocacy groups have called for a dedicated ICD-10 code to improve diagnosis tracking and treatment validation, confirmation of a specific new code in the official CDC ICD-10-CM FY2026 update could not be independently verified at the time of writing.

Why this matters for aesthetic clinics

Dermatology and aesthetic clinics that treat skin conditions may encounter clients who have experienced topical steroid withdrawal. Understanding the clinical landscape — and the limitations of current evidence — helps clinics communicate responsibly about this emerging area.

A PubMed search for "topical steroid withdrawal" returns a growing body of literature, including case reports, case series, and reviews. However, the condition remains debated in terms of diagnostic criteria, prevalence, and whether it represents a distinct clinical entity or a subset of steroid-rosacea or rebound phenomena.

What clinics should consider

  1. Clinical recognition is growing but not complete. While TSW is increasingly discussed in dermatology literature, the lack of a confirmed dedicated ICD-10 code means diagnosis tracking and prevalence data remain limited.

  2. Communication should be cautious. Clinics should avoid presenting TSW as a fully validated, universally recognized diagnosis. It is better described as an emerging clinical phenomenon with ongoing research.

  3. Client concerns are real regardless of code status. Clients who believe they have experienced TSW need empathetic, evidence-aware communication — not dismissal or overvalidation.

  4. Dermatology referral for suspected TSW. Aesthetic clinics should refer suspected TSW cases to dermatology rather than attempting to manage steroid withdrawal independently.

Practical takeaway

Aesthetic clinics should be aware of topical steroid withdrawal as an emerging clinical topic, communicate about it cautiously, and refer suspected cases to dermatology.

How Glowgau supports this workflow

Glowgau helps clinics structure their consultation intake — capturing skin concerns, medication history, and treatment context so that the right information reaches the right specialist. Try Glowgau at https://glowgau.com, or contact contact@glowgau.com with questions.

Read more

Verification and publication

Verified and published by Dr. C. Alahakoon, Clinician and Clinical Data Scientist. LinkedIn: www.linkedin.com/in/chandimal-alahakoon-ln

References

  1. Dermatology Times newsletter, July 2026. Reference to new ICD-10 code for topical steroid withdrawal. Original article behind Cloudflare paywall — not directly accessed.
  2. CDC ICD-10-CM FY2026 Browser Tool. Search for "topical steroid withdrawal" and related terms conducted July 2026 — no dedicated code confirmed.
  3. PubMed search for "topical steroid withdrawal" — growing body of case reports and reviews, no consensus diagnostic criteria established.